BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26423244)

  • 1. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
    Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
    Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
    Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
    Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Antimicrobial Stewardship and Molecular Rapid Diagnostic Tests on Antimicrobial Prescribing for Extended-Spectrum Beta-Lactamase- and Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae in Bloodstream Infection.
    Kunz Coyne AJ; Casapao AM; Isache C; Morales J; McCarter YS; Jankowski CA
    Microbiol Spectr; 2021 Oct; 9(2):e0046421. PubMed ID: 34704795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.
    Kim YK; Pai H; Lee HJ; Park SE; Choi EH; Kim J; Kim JH; Kim EC
    Antimicrob Agents Chemother; 2002 May; 46(5):1481-91. PubMed ID: 11959586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters.
    Cheng WL; Hsueh PR; Lee CC; Li CW; Li MJ; Chang CM; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2016 Apr; 49(2):208-15. PubMed ID: 25070279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Quirante OF; Cerrato SG; Pardos SL
    Braz J Infect Dis; 2011; 15(4):370-6. PubMed ID: 21861009
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
    Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.
    Yang CC; Li SH; Chuang FR; Chen CH; Lee CH; Chen JB; Wu CH; Lee CT
    BMC Infect Dis; 2012 Sep; 12():206. PubMed ID: 22947300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
    Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
    Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteremia Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Vientiane, Lao PDR: A 5-Year Study.
    Chang K; Rattanavong S; Mayxay M; Keoluangkhot V; Davong V; Vongsouvath M; Luangraj M; Simpson AJH; Newton PN; Dance DAB
    Am J Trop Med Hyg; 2020 May; 102(5):1137-1143. PubMed ID: 32157990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae.
    Katip W; Yoodee J; Uitrakul S; Oberdorfer P
    Sci Rep; 2021 Jan; 11(1):18. PubMed ID: 33420122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
    Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
    Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.